Literature DB >> 26725186

Using a Low-Risk Population to Estimate the Specificity of the World Heart Federation Criteria for the Diagnosis of Rheumatic Heart Disease.

Bradley C Clark1, Anita Krishnan2, Robert McCarter3, Janet Scheel2, Craig Sable2, Andrea Beaton2.   

Abstract

BACKGROUND: The 2012 World Heart Federation (WHF) criteria set the minimum standards for echocardiographic diagnosis of rheumatic heart disease (RHD) in a high-risk population without history of acute rheumatic fever. The high sensitivity of the 2012 WHF criteria is well accepted, but the specificity cannot be directly assessed without a confirmatory test. The objective of this study was to estimate the false-positive rate of the WHF criteria through their application in a population at very low risk for RHD.
METHODS: The Children's National Health System echocardiography database was searched for patients (6-15 years of age) with an International Classification of Diseases, Ninth Revision, code for "chest pain." Chart review was performed; children with congenital heart disease or systemic disease were excluded. Patients were classified according to WHF criteria as having normal, borderline, or definite RHD on the basis of mitral and aortic valve morphology and the presence of pathologic mitral and/or aortic regurgitation.
RESULTS: A total of 1,251 studies were identified, and 152 were excluded. Fifty studies were randomly chosen from each age, with equal gender distribution, for a total of 500 echocardiograms. No patients met the criteria for definite RHD and four (0.8%) for borderline RHD, both by pathologic mitral regurgitation. No patients met the criteria for borderline RHD on the basis of mitral valve morphology or pathologic aortic regurgitation.
CONCLUSION: In a US pediatric population, no children had findings of definite RHD, and 0.8% had findings of borderline RHD, most likely representing false-positive results. Although there appears to be some overlap between the findings of borderline RHD and those in the normal pediatric population, our data suggest acceptable specificity for all RHD, with excellent specificity for definite RHD.
Copyright © 2016 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aortic regurgitation; Echocardiogram; Mitral regurgitation; Rheumatic heart disease; World Heart Federation criteria

Mesh:

Year:  2015        PMID: 26725186     DOI: 10.1016/j.echo.2015.11.013

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  4 in total

1.  Decreased Prevalence of Rheumatic Heart Disease Confirmed Among HIV-positive Youth.

Authors:  Ian W Hovis; Judith Namuyonga; Grace P Kisitu; Emma Ndagire; Emmy Okello; Chris T Longenecker; Amy Sanyahumbi; Craig A Sable; Daniel J Penny; Peter Lwabi; Adeodata R Kekitiinwa; Andrea Beaton
Journal:  Pediatr Infect Dis J       Date:  2019-04       Impact factor: 2.129

2.  Screening-detected rheumatic heart disease can progress to severe disease.

Authors:  Daniel Engelman; Gavin R Wheaton; Reapi L Mataika; Joseph H Kado; Samantha M Colquhoun; Bo Remenyi; Andrew C Steer
Journal:  Heart Asia       Date:  2016-11-28

3.  Inter-rater and intra-rater reliability and agreement of echocardiographic diagnosis of rheumatic heart disease using the World Heart Federation evidence-based criteria.

Authors:  Bo Remenyi; Jonathan Carapetis; John W Stirling; Beatrice Ferreira; Krishnan Kumar; John Lawrenson; Eloi Marijon; Mariana Mirabel; A O Mocumbi; Cleonice Mota; John Paar; Anita Saxena; Janet Scheel; Satu Viali; I B Vijayalakshmi; Gavin R Wheaton; Liesl Zuhlke; Karishma Sidhu; Eliazar Dimalapang; Thomas L Gentles; Nigel J Wilson
Journal:  Heart Asia       Date:  2019-06-24

4.  Prevalence of rheumatic valvular heart disease in Rwandan school children: echocardiographic evaluation using the World Heart Federation criteria.

Authors:  J Mucumbitsi; B Bulwer; L Mutesa; V Ndahindwa; M Semakula; E Rusingiza; P Arya; S Breakey; C Patton-Bolman; E L Kaplan
Journal:  Cardiovasc J Afr       Date:  2017-03-01       Impact factor: 1.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.